PharmaTelevision - Chroma Therapeutics’ Deal with GlaxoSmithKline

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Chroma Therapeutics’ Deal with GlaxoSmithKline

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

At the BIA Leadership Summit, Dr Fintan Walton spoke to Ian Nicholson, CEO of Chroma Therapeutics. They discussed:

• Chroma’s deal with GSK

• the key to Chroma’s novel chemistry platform technology and the importance of having a platform when running a biotech company

• biotech funding and the importance of government support for the industry

• how deal making has changed in the last 20 years, including the relationship and negotiating power between pharma and biotech companies

• the next big thing to come out of Chroma

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The key to Chroma Therapeutics's novel chemistry platform technology.

Fintan Walton:

Hello and welcome to PharmaVentures business review here at the BIA Leadership Summit here in Hertfordshire in the UK. On this show I have Ian Nicholson, who is the CEO of Chroma Therapeutics. Welcome to the show.

Ian Nicholson:

Thank you, Fintan Walton.

Fintan Walton:

Ian Nicholson, as I said you head up Chroma Therapeutics, Chroma Therapeuticsis based in Oxford, or near Oxford in the UK. You are a biotech company emerging with new technologies with new capabilities, could you describe for us what Chroma Therapeutics is about, your technology and where your company is positioned in the biotech industry?

Ian Nicholson:

Yes of course Fintan Walton. So we are really an emerging pharmaceutical company in many respects. Primarily based around a discovery and development platform. The company really has two aspects to it's asset base. The first is a set of clinical oncology assets which are all small molecules. Initially the company was founded around chromatin and chromatin based targets, so we have three assets in the clinic now. Our lead asset is a protein pivotal studies in the second half of this year in 2009, but in addition to that we have a very interesting and quite novel chemistry platform technology, which is really quite an unique platform that gives rise to the ability to target small molecule drugs orally to leverage small molecule drugs to macrophages and monocytes. And we think this is a very robust platform that can be applied not only in a different variety of therapeutic settings but also across the range of targets and chemistries.

Fintan Walton:

So the origins was around obviously around chromatin ?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ian Nicholson

Chief Executive Officer

Ian Nicholson joined Chroma Therapeutics in September 2004. Prior to joining Chroma Therapeutics, he was Senior Vice President of Business Development for Celltech, responsible for all global licensing activities, and additionally held the position of Acting CEO, Oxford GlycoSciences following its acquisition by Celltech. Prior to this he was Commercial Director at Oxford Asymmetry and has held a variety of senior commercial positions with Lonza and Amersham. He holds a BSc (Hons) degree from University College, London and an MBA from Boston University.

Chroma Therapeutics

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma Therapeutics is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma Therapeutics aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.